CellSource Co

CellSource Co Debt

The Debt of CellSource Co (4880.T) as of Oct 27, 2026 is 56.72 M JPY. In the previous year, Debt was 77.29 M JPY — a change of -26.62% (lower).

Debt

56.72 MJPY

YoY

-26.62%

Last updated:

In 2025, CellSource Co's total debt was 56.72 M JPY, a -26.62% change from the 77.29 M JPY total debt recorded in the previous year.

The CellSource Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
7.32 M JPY
Jan 1, 2020
4.29 M JPY
Jan 1, 2021
1.10 M JPY
Jan 1, 2022
0.00 JPY
Jan 1, 2023
97.54 M JPY
Jan 1, 2024
77.29 M JPY
Jan 1, 2025
56.72 M JPY
The CellSource Co Debt history
YEARDebtYoY
56.72 MJPY-26.62%
77.29 MJPY-20.76%
97.54 MJPY—
0.00JPY-100.00%
1.10 MJPY-74.40%
4.29 MJPY-41.49%
7.32 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding CellSource Co's Debt Structure

CellSource Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing CellSource Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to CellSource Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in CellSource Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about CellSource Co stock

Debt of CellSource Co is 56.72 M JPY in 2025.

Debt of CellSource Co changed from 77.29 M JPY to 56.72 M JPY, representing a -26.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt CellSource Co since 2006 – with annual values, charts, and detailed analysis.

Debt's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CellSource Co

All Key Metrics — CellSource Co